| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | 0.0073 | 0.8 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | 0.0098 | 0.8 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | -0.0082 | 0.8 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.008 | 0.8 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.8 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.0071 | 0.8 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | -0.0077 | 0.8 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | 0.036 | 0.8 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.0067 | 0.8 |